6-OHDA Injections in Mice to Model Parkinson’s Disease
Unilateral 6-hydroxydopamine (6-OHDA) injections in the mouse dorsal striatum (caudate putamen) lead to a strong Parkinson’s disease pathology in the injected brain hemisphere, while the contralateral hemisphere can serve as control. The effect of the 6-OHDA injection can be validated histologically, by measurement of tyrosine hydroxylase (TH) levels in the dorsal striatum that is strongly …
Cisterna Magna Injections – Now Available for Preclinical Studies
Cisterna magna injections are the most favorable administration route of cells and various agents to ensure their distribution to more rostral brain regions in mice and rats compared to intrathecal injections. Furthermore, injections of various tracer molecules into the cisterna magna are used to track the cerebrospinal fluid´s (CSF) movement through the glymphatic system in …
LRRK2 G2019S Mice and Rats to Model Parkinson’s Disease
The LRRK2 G2019S gain-of-function mutation is frequently observed in Parkinson’s disease patients. Selective LRRK2 inhibitors have thus been proposed as promising compounds for the treatment of PD. At Scantox, two rodent models are now available to test your LRRK2 inhibitors. LRRK2-G2019S Knock-In mice expressing murine LRRK2 with G2019S mutation and human LRRK2 G2019S transgenic rats …
In Vivo Cerebrospinal Fluid Sampling in Rodents
Scantox now offers repeated in vivo cerebrospinal fluid (CSF) sampling. Collection of CSF samples from the same animal at different time points allows for longitudinal sample analysis of the same animal, significantly reducing the number of animals needed per group and study. Depending on the project design, in vivo CSF collection represents a procedure that …
Cyclodextrin is an Effective Reference Compound for NPC1-/- Mouse Studies
The strong pathology of NPC1-/- mice, a Niemann-Pick type 1 mouse model, can be significantly reduced by cyclodextrin treatment. Here we show that cyclodextrin (2-hydroxypropyl-ß-cyclodextrin, HPBCD improves cholesterol levels as well as liver enzyme levels. Subcutaneous treatment of NPC1-/- mice once weekly for 3 weeks thus reduces liver cholesterol levels (Fig.1A) while increasing plasma triglyceride …